Cormorant Asset Management, LP 13D and 13G filings for VYNE Therapeutics Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-11-14 1:10 pm Sale | 2025-09-30 | 13G | VYNE Therapeutics Inc. VYNE | Cormorant Asset Management, LP | 0 0.000% | -1,370,938 (Position Closed) | Filing |
| 2025-08-14 3:04 pm Sale | 2025-06-30 | 13G | VYNE Therapeutics Inc. VYNE | Cormorant Asset Management, LP | 1,370,938 8.230% | -478,652 (-25.88%) | Filing |
| 2025-05-19 5:47 pm Purchase | 2025-03-31 | 13G | VYNE Therapeutics Inc. VYNE | Cormorant Asset Management, LP | 1,849,590 9.990% | 1,849,590 (New Position) | Filing |
| 2025-05-15 3:03 pm Unchanged | 2025-03-31 | 13G | VYNE Therapeutics Inc. VYNE | Cormorant Asset Management, LP | 0 0.000% | 0 (Unchanged) | Filing |